The latest trends in domestic *** preparation market

Business Club April 14 News Recently, the federal pharmaceutical company announced that the group has three applications for the production of insulin formulations have been approved, so that the federal pharmaceutical's insulin products from two to five, the three new products belong to the reorganization Insulin formulations, R, 30R, 50R, respectively. These new products help federal pharmaceuticals expand their market share in diabetes medications.

In fact, with the increase in the prevalence of diabetes, the improvement of people’s living standards and the improvement of medical standards, the market for diabetes drug use in China is expanding year by year. In 2009, the market for diabetes drug use in China was close to 10 billion, an increase of 15.09% year-on-year.

The products for treating diabetes mainly include insulin preparations, acarbose, metformin, repaglinide, rosiglitazone, and the like. According to the Minet research report, the market shares of insulin therapeutics and acarbose in the market share of diabetes drug treatment medicines are ranked in the top two, with the insulin market share steadily increasing in recent years, accounting for more than one-third of the market share in 2009. Diabetes drug market share.

Insulin preparations can be divided into protamine zinc insulin, single-component insulin, insulin lispro, insulin aspart, and insulin glargine according to varieties. According to the competitive pattern of clinical drug use by Minet-Chemicals, there are three insulin varieties that have entered the top 10 positions in the diabetes drug market, namely, single component insulin, insulin glargine and insulin aspart30.

The insulin preparation market is dominated by foreign-invested products. The top three manufacturers in the market share are Danish Novo Nordisk (main products: Novolin), Eli Lilly (main products: Humulin), Sanofi- Aventis (main products: come to the time), the three together occupy more than 90% of the market share, the domestic manufacturers a total of less than 10% of the market share, the main domestic manufacturers are Tonghua Dongbao Pharmaceutical (main products: Gan Shulin), Gan Li Pharmaceutical (main products: Chang Xiuling), Jiangsu Wanbang Biochemical (main products: Wan Banglin), etc.